Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Fleshner

Showing results (221-230 of 260) with videos related to

Pageof 26
Sort By:
Cancer Medicine|July 13, 2021
Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223Esmail M Al-Ezzi, Husam A Alqaisi, Marco A J Iafolla, et al.
European Urology|August 14, 2012
Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancerSean C Skeldon, Kara Semotiuk, Melyssa Aronson, et al.
BJU International|December 18, 2023
Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancerChristian Vitug, Katherine Lajkosz, Julian Chavarriaga, et al.
Journal of the National Cancer Institute|June 5, 2019
Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA TranscriptomeJouhyun Jeon, Ekaterina Olkhov-Mitsel, Honglei Xie, et al.
International Journal of Radiation Oncology, Biology, Physics|August 28, 2022
Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate CancerRachel M Glicksman, Matthew Ramotar, Ur Metser, et al.
The Prostate|February 18, 2021
Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysisMarian S Wettstein, Luke A David, Clinsy Pazhepurackel, et al.
European Urology|July 19, 2020
Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized CohortAntonio Finelli, Douglas C Cheung, Ashraf Al-Matar, et al.
BJU International|March 28, 2012
Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancerBas W G van Rhijn, Liyang Liu, André N Vis, et al.
BMC Urology|September 12, 2018
The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validationVéronique Ouellet, Armen Aprikian, Alain Bergeron, et al.
Oncotarget|January 28, 2016
Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometryColleen N Biggs, Khurram M Siddiqui, Ali A Al-Zahrani, et al.
Pageof 26

Showing results (221-230 of 260) with videos related to

Sort By:
Pageof 26
Cancer Medicine|July 13, 2021
Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223Esmail M Al-Ezzi, Husam A Alqaisi, Marco A J Iafolla, et al.
European Urology|August 14, 2012
Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancerSean C Skeldon, Kara Semotiuk, Melyssa Aronson, et al.
BJU International|December 18, 2023
Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancerChristian Vitug, Katherine Lajkosz, Julian Chavarriaga, et al.
Journal of the National Cancer Institute|June 5, 2019
Temporal Stability and Prognostic Biomarker Potential of the Prostate Cancer Urine miRNA TranscriptomeJouhyun Jeon, Ekaterina Olkhov-Mitsel, Honglei Xie, et al.
International Journal of Radiation Oncology, Biology, Physics|August 28, 2022
Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate CancerRachel M Glicksman, Matthew Ramotar, Ur Metser, et al.
The Prostate|February 18, 2021
Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysisMarian S Wettstein, Luke A David, Clinsy Pazhepurackel, et al.
European Urology|July 19, 2020
Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized CohortAntonio Finelli, Douglas C Cheung, Ashraf Al-Matar, et al.
BJU International|March 28, 2012
Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancerBas W G van Rhijn, Liyang Liu, André N Vis, et al.
BMC Urology|September 12, 2018
The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validationVéronique Ouellet, Armen Aprikian, Alain Bergeron, et al.
Oncotarget|January 28, 2016
Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometryColleen N Biggs, Khurram M Siddiqui, Ali A Al-Zahrani, et al.
Pageof 26